Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Sertraline in Diabetic Neuropathy: Preliminary Results

Sertraline in Diabetic Neuropathy: Preliminary Results Previous research has shown that antidepressants have been useful in the treatment of pain, particularly diabetic neuropathy. This study was an initial open investigation into the use of sertraline in diabetic neuropathy. Eight patients with diabetic neuropathy but not depression were treated with increasing doses of sertraline to a maximum of 150 mg/day for 8 weeks. Sertraline treatment led to significant reductions in mean visual analog scale (VAS) ratings, e.g., pain from 71.2 to 23.1 (t = 3.74, p < .01) and paresthesias from 53.8 to 15.0 (t = 4.15, p < .01). Baseline platelet serotonin (5HT) content also correlated significantly with improvement in pain (r = 0.70, p = 05). Plasma sertraline (SRT) correlated with improvement in paresthesias (r = 0.70). Conclusion: This preliminary result indicates the potential application of sertraline to treatment of diabetic neuropathy. A replication is now underway. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Clinical Psychiatry Springer Journals

Sertraline in Diabetic Neuropathy: Preliminary Results

Download PDF
3 pages

Loading next page...
 
/lp/springer-journals/sertraline-in-diabetic-neuropathy-preliminary-results-Ch4pZbDz8O
Publisher
Springer Journals
Copyright
Copyright © 1997 by American Academy of Clinical Psychiatrists
Subject
Medicine & Public Health; Neurology; Psychiatry; Psychopharmacology
ISSN
1040-1237
eISSN
1573-3238
DOI
10.1023/A:1022360528151
Publisher site
See Article on Publisher Site

Abstract

Previous research has shown that antidepressants have been useful in the treatment of pain, particularly diabetic neuropathy. This study was an initial open investigation into the use of sertraline in diabetic neuropathy. Eight patients with diabetic neuropathy but not depression were treated with increasing doses of sertraline to a maximum of 150 mg/day for 8 weeks. Sertraline treatment led to significant reductions in mean visual analog scale (VAS) ratings, e.g., pain from 71.2 to 23.1 (t = 3.74, p < .01) and paresthesias from 53.8 to 15.0 (t = 4.15, p < .01). Baseline platelet serotonin (5HT) content also correlated significantly with improvement in pain (r = 0.70, p = 05). Plasma sertraline (SRT) correlated with improvement in paresthesias (r = 0.70). Conclusion: This preliminary result indicates the potential application of sertraline to treatment of diabetic neuropathy. A replication is now underway.

Journal

Annals of Clinical Psychiatry – Springer Journals

Published: Sep 18, 2004

References

  • Treatment of depression in patients with diabetes mellitus
    Goodnick, PJ; Henry, JH; Buki, VMV
  • Effects of inhibitors of 5-hydroxytryptamine uptake on plasma glucose and their interaction with 5-hydroxytryptophan in producing hypoglycemia in mice
    Wilson, GA; Furman, BL
  • Harrison's Principles of Internal Medicine
    Wilson, JD; Braunwald, E; Isselbacherr
  • Cecil Essentials of Medicine
  • Antidepressants in the treatment of diabetic neuropathy symptoms
    Sindrup, SH
  • Effects of desipramine, amitriptyline, and fluoxetine in diabetic neuropathy
    Max, MB; Lynch, SA; Muir, J
  • Clomipramine vs. desipramine vs. placebo in the treatment of diabetic neuropathy symptoms: A double-blind crossover study
    Sindrup, SH; Gram, LF; Skjold, T
  • Concentration-response relationship in paroxetine treatment of diabetic neuropathy symptoms: A patient-blinded dose-escalation study
    Sindrup, SH; Grodum, E; Gram, LF
  • Sertraline in coexisting major depression and diabetes mellitus
    Goodnick, PJ; Kumar, A; Henry, JH
  • A modified HPLC technique for simultaneous measurement of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in cerebrospinal fluid, platelets, and plasma
    Kumar, AM; Kumar, M; Krishnaprasad, D
  • New antidepressant agents: Recent pharmacological developments leading to improved efficacy
    Goodnick, PJ; Benitez, A
  • Neurochemistry and paroxetine response in major depression
    Goodnick, PJ; Henry, J; Kumar, A